Detail akcie Contineum The Rg-A online

Business Summary: Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Contineum Therapeutics Inc revenues was not reported. Net loss increased 62% to $44.8M. Higher net loss reflects discovering and developing novel, oral small molecule therap segment loss increase from $13M to $50.9M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.08 to -$1.69.